Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1432-0843

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment ; volume:88 ; number:5 ; day:29 ; month:7 ; year:2021 ; pages:825-836 ; date:11.2021
Cancer chemotherapy and pharmacology ; 88, Heft 5 (29.7.2021), 825-836, 11.2021

Classification: Medizin, Gesundheit

Creator: Akce, Mehmet
El-Khoueiry, Anthony
Piha-Paul, Sarina A.
Bacque, Emeline
Pan, Peng
Zhang, Zhi-Yi
Ewesuedo, Reginald
Gupta, Divya
Tang, Yongqiang
Milton, Ashley
Zajic, Stefan
Judson, Patricia L.
O’Bryant, Cindy L.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00280-021-04329-8

URN: urn:nbn:de:101:1-2021121906373989046405

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Akce, Mehmet
El-Khoueiry, Anthony
Piha-Paul, Sarina A.
Bacque, Emeline
Pan, Peng
Zhang, Zhi-Yi
Ewesuedo, Reginald
Gupta, Divya
Tang, Yongqiang
Milton, Ashley
Zajic, Stefan
Judson, Patricia L.
O’Bryant, Cindy L.
SpringerLink (Online service)

Other Objects (12)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

Related objects

Reset password